Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 35,000 Shares

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $27.52, for a total value of $963,200.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Robert Berman also recently made the following trade(s):

  • On Tuesday, December 19th, Robert Berman sold 10,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $24.10, for a total value of $241,000.00.
  • On Monday, December 11th, Robert Berman sold 25,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $21.28, for a total value of $532,000.00.
  • On Thursday, November 9th, Robert Berman sold 27,423 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.60, for a total value of $729,451.80.
  • On Tuesday, November 14th, Robert Berman sold 160,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.76, for a total value of $4,121,600.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) traded up $0.31 during trading on Friday, hitting $26.44. The stock had a trading volume of 195,387 shares, compared to its average volume of 355,300. Biohaven Pharmaceutical Holding Co Ltd has a fifty-two week low of $17.00 and a fifty-two week high of $39.51. The stock has a market capitalization of $1,100.00 and a P/E ratio of -5.07.

Several institutional investors have recently made changes to their positions in BHVN. Legal & General Group Plc purchased a new position in shares of Biohaven Pharmaceutical in the third quarter valued at about $119,000. Nationwide Fund Advisors purchased a new position in shares of Biohaven Pharmaceutical in the third quarter valued at about $214,000. American International Group Inc. purchased a new position in shares of Biohaven Pharmaceutical in the third quarter valued at about $251,000. State of Wisconsin Investment Board purchased a new position in shares of Biohaven Pharmaceutical in the third quarter valued at about $262,000. Finally, Susquehanna International Group LLP bought a new stake in shares of Biohaven Pharmaceutical in the third quarter worth about $302,000. Institutional investors and hedge funds own 47.76% of the company’s stock.

Several equities analysts recently weighed in on BHVN shares. Piper Jaffray Companies set a $48.00 target price on Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, December 11th. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Monday, December 4th. Needham & Company LLC restated a “buy” rating and issued a $36.00 price objective on shares of Biohaven Pharmaceutical in a research report on Wednesday, November 15th. BidaskClub downgraded Biohaven Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. Finally, Canaccord Genuity began coverage on Biohaven Pharmaceutical in a research report on Friday, December 15th. They issued a “buy” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $36.14.

ILLEGAL ACTIVITY WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 35,000 Shares” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/12/biohaven-pharmaceutical-holding-co-ltd-bhvn-insider-robert-berman-sells-35000-shares.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit